About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

Blue having one of his episodes! Please ignore.

You got it Laurie !! :)

INTERIM RESULTS - SIX MONTHS ENDED 31 DECEMBER 2006

Highlights:

cancer collaboration with multinational diagnostics business bioMerieux S.A.
- announced 12 July 2006;
in vivo studies on the company's ERX3722 candidate molecule showed 50%
reduction in breast cancer tumour size without evidence of systemic toxicity
- reported in September 2006;
500,000 in additional funds raised by share placing in September 2006.

Post Balance Sheet Highlight

500,000 in additional funds raised by share placing in January 2007.

http://moneyam.uk-wire.com/cgi-bin/articles/200703300900070451U.html

Prospects

In the current reporting period we have focused on development and exploitation
of our EnPAD(TM) drug discovery technology, which we believe underpins our future
success as a developer of new and better cancer medicines. Inspired by the
success of our work on targeting of the wnt/beta-catenin signalling pathway,
EiRx will continue to invest in EnPAD(TM) and to pursue the development of
promising molecules emerging from these screens, thereby creating value from the
apoptosis research we have undertaken in previous years.

As intimated in our annual report released in December 2006, we believe that we
can best capitalise on the value of our product development efforts by advancing
our candidate therapies at least as far as the late preclinical stage of
development. Reaching this stage will require further investment in the
development of hit compounds from EnPAD(TM) programmes into clinical candidates.
Where appropriate we will seek to develop the necessary skills and competencies
in-house, but academic and commercial partnerships are to be preferred in
instances where they can deliver savings in time or cost. Your board is
considering multiple routes to acquiring the new capabilities we need, including
grant funding, partnering with larger businesses and in-licensing and M&A
options as and when such opportunities arise.

I look forward over the coming months to sharing with you further news of our
progress and our expanding vision for the Company's future. Lastly, I would
like to thank all the management and staff of EiRx for their continued hard work
and commitment and our investors for their continued support.

EiRx Therapeutics PLC - Interim Results for the six months ended 31 December
2006

Your board is
considering multiple routes to acquiring the new capabilities we need, including
grant funding, partnering with larger businesses and in-licensing and M&A
options as and when such opportunities arise.


well that kind of backs up the JV rumour, I understand ERX did not want to deliver results until next week as there is more news they wanted to add, but were forced by there brokers to issue the results.

PH
I agree still happy to hold and accumulate.

Mike111D - 4 Apr'07 - 23:23 - 13198 of 13203


ZYC300 gets a mention as part of the MGI programme for focussed pipeline investments, as per the presentation delivered at the Lehman Brothers 10th annual global healthcare conference on March 20th 2007:

http://library.corporate-ir.net/library/73/738/73842/items/236522/LehmanBrothersPresentation.pdf

Increasing focus being given to the MGI development pipeline, calling out ZYC300:

MGI has decided to consolidate its drug-development operations from its headquarters in Minnesota and a facility in Baltimore to the former Zycos location in Lexington, with plans to nearly triple the number of workers the company now employs in Massachusetts, according to the company's chief scientific officer, Mary Lynne Hedley.

Hedley said that work at the Lexington facility would involve developing MGI's approved cancer drug Dacogen for additional uses as well as bringing the company's other key cancer drug candidates, such as Amolimogene and ZYC300, through clinical trials.

http://masshightech.bizjournals.com/masshightech/stories/2007/01/29/story10.html

As we know trial results for a study of ZYC300 administered with Cyclophosphamide are due this month:

http://clinicaltrials.gov/ct/show/NCT00381173;jsessionid=631F1AF72EC7FC29976FE9B2A6BC793B?order=38

http://utm-ext01a.mdacc.tmc.edu/dept/prot/clinicaltrialswp.nsf/Index/2006-0488

Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy

Purpose: The carcinogen activator cytochrome P450 1B1 (CYP1B1) is expressed on almost all human tumors with rare expression on normal tissues. Anti-CYP1B1-specific T cells kill CYP1B1-expressing tumors, providing the rationale to examine CYP1B1 as a target for immunotherapy. Experimental Design: ZYC300, a plasmid DNA of CYP1B1 encapsulated in biodegradable polyDL-lactide-coglycolide microparticles, was used in a phase I clinical trial to treat 17 patients with advanced stage, progressive cancer. ZYC300 was administered i.m. at a fixed dose of 400 μg every other week for up to 12 doses. Results: Thirteen patients received six vaccinations and five received all 12 doses. No significant adverse events were observed. Six patients developed immunity to CYP1B1, three of whom developed disease stabilization. All but 1 of 11 patients who did not develop immunity to CYP1B1 progressed and did not respond to salvage therapy. Five patients who developed immunity to CYP1B1 required salvage therapy for progressive metastatic disease and showed marked response to their next treatment regimen, most of which lasted longer than 1 year. Conclusions: The association between immunity to CYP1B1 and response to next salvage therapy was not expected. Because six of the seven patients who had clinical benefit regardless of the nature of salvage therapy had developed immunity to CYP1B1, it seems highly unlikely that this occurred by chance alone. Regardless of the mechanism(s) that induced tumor regression, these findings force us to rethink how the generation of antitumor immunity might be integrated into the treatment of cancer.

http://cat.inist.fr/?aModele=afficheN&cpsidt=16856410

potatohead is a mad ramper. He calls himself BlueXXXX ( XXX = Kitten, Dolphin, etc) on a d v f n and he tells very big lies, he makes things up about ERX, joint ventures, M&A with Johnson & Johnson/GSK. Claims that other companies drug candidates belong to ERX etc. You would be very wise to ignore absolutely everything he says and do your own research.

gilbertD1
We all know who ph is most of us were already on this share before he arrived cheers for the advice anyway.

There was a reference to the ZYC300 In MGI web cast last night not that it will efect the SP of Erx .

Of Interest The MGI Pharma Results

http://home.businesswire.com/portal/site/home/index.jsp?epi-content=NEWS_VIEW_POPUP_TYPE&newsId=20070418006079&ndmHsc=v2*A1174388400000*B1176992393000*DgroupByDate*J2*L1*N1000837*ZMGI&newsLang=en&beanID=202776713&viewID=news_view_popup

smiler "not that it will efect the SP"
It's up 2.7%

Still .2 up but I think I will wait a bit before I sell ! as we know this share is up & down but could be worth the wait ! :)

there was some speculation on the Dark Side this morning about the Edinburgh University having a link with erx with some research, Is there any truth to this or was it a porkie ? I can not get back on to the dark side it comes up server error !!

Connection highly unlikely.

this looks doomed.. bound to be news coming then

Anyone know whats going on ERX today?

Looks like it's going up and down triggered by a couple of large sells.

guess on a positive note ,PH has finally stopped posting his drivel on here for the last 2 weeks.

WINGNUT
Looks like his sold out, all we want now is the sp to go to 3p to really rub it in.

no i have not